Specialty Vision is an online directory, not a healthcare provider. Listed practices are not owned or operated by us.

Specialty Vision is an online directory and does not provide healthcare services. Listed practices and doctors are not owned, operated, or employed by Specialty Vision.

Eye Drops Instead of Injections for Dry AMD: Where the Research Actually Stands

Eye Drops for Dry AMD at a Glance

Eye Drops for Dry AMD at a Glance

Do you have dry age-related macular degeneration (AMD) and hope to swap a needle for a bottle of drops? Today the honest answer is no. There is no eye drop approved to treat dry AMD, and the only medicines approved to slow its advanced stage are given as shots into the eye1. That is frustrating, but it is not the whole story. For most people with dry AMD, the mainstay is not a needle at all. Researchers are also testing new options, including one eye drop still in early trials. This page walks through what is proven, what is experimental, and how to read the headlines you may see.

There is no treatment for early dry AMD, but for intermediate dry AMD special oral supplements may lower the chance of it progressing to the late, sight-threatening stage2. For the advanced form, called geographic atrophy, two injectable medicines can modestly slow how fast the damage spreads3. Neither is a cure. Neither restores vision you have already lost. Knowing that up front helps you weigh any treatment, and any headline, against a realistic yardstick rather than a hope for a quick fix.

What Dry AMD and Geographic Atrophy Are

The macula is the small central part of the retina you use for sharp, straight-ahead vision. Dry AMD is the most common form of macular degeneration, in which the macula slowly thins with age, and AMD affects about 11 million people in the United States2. Early dry AMD usually causes no symptoms at all. That is why it is often first found at a routine dilated eye exam, not because something looks wrong to you.

Over years, some people reach the late stage of dry AMD. In late dry AMD, called geographic atrophy, patches of the light-sensing retina wear away, straight lines can start to look wavy, and a blurry area grows near the center of vision2. This is the stage the newest injectable drugs target. Geographic atrophy is different from wet AMD, in which new leaky blood vessels grow. Wet AMD has its own, separate shots and is not the subject of this page.

The macula sits at the back of the eye, behind the lens and the gel that fills the eyeball. A drop on the surface has to cross a long distance and several barriers to reach it in a useful dose. That is a big reason nearly every treatment that has reached late-stage testing is given by a shot into the eye, or in some cases by a pill that travels through the blood. Getting enough of a drug to the retina from a drop is a real scientific hurdle, not a gap that companies simply overlooked.

Where the Research on Eye Drops Actually Stands

Whatever you read on supplement labels or wellness sites, no eye drop is currently approved to treat dry AMD or geographic atrophy1. Approval matters. It means a treatment was tested in careful trials and shown to do more good than harm. A product sold as a 'macular support' drop without that testing has not cleared that bar, and there is no good evidence that it slows the disease. If a drop could safely reach and protect the macula, it would be a major advance. That is exactly why it is being studied, not already sold.

The two treatments now on the market for geographic atrophy are both eye shots that work by quieting part of the immune system, called the complement pathway1. They are given into the eye about once a month or every other month3. For earlier dry AMD, the proven step is not a shot but an oral supplement, described below. So the real choice today is usually between supplements and monitoring on one hand, and shots for advanced disease on the other. It is not a choice between drops and shots.

The AREDS and AREDS2 studies tested a daily supplement of vitamins C and E, lutein, zeaxanthin, zinc and copper. In people whose geographic atrophy started away from the very center of vision, the supplement slowed how fast the atrophy spread toward the center by about 55 percent over roughly three years4. That is a meaningful slowdown, drawn from two large trials rather than one small one. It is not a reversal. The benefit was small for people whose atrophy had already reached the center. Still, it is the best-supported thing most people with dry AMD can do.

Experimental Treatments Still in the Pipeline

Yes, but it is early. In the current geographic atrophy research pipeline almost every candidate is a shot or a pill, with one experimental eye drop, called GAL-101, being tested against a placebo in the early-stage eDREAM trial5. Being in a trial is not the same as being proven. GAL-101 has not been shown to slow dry AMD, and like any experimental treatment it may or may not succeed. Treat any 'eye drop for AMD' you can buy today as unproven, because none has passed the tests this one is only now beginning.

Beyond the two approved shots, other dry AMD treatments in later-stage trials are also being given as eye shots or as pills1. Some experimental shots aim at the same immune pathway from a different angle. Some pills try to reduce the buildup of waste products in the retina. A few approaches even use a once-daily shot under the skin rather than into the eye. The direction of travel is real progress, but it is still mostly toward shots and pills, not drops.

An experimental treatment can look promising in a laboratory or an early study and still fail when it is tested in more people. That is not a flaw in the process; it is the process working. If a trial appeals to you, joining can be a reasonable and generous thing to do. Go in understanding that you might receive a placebo, and that the goal is to answer a question, not to guarantee you a benefit. Your retina specialist can tell you whether a trial near you is a sensible fit.

How Strong Is the Evidence?

Two things rest on strong evidence. The AREDS-type supplement finding comes from two large randomized trials, the gold standard for this kind of question4. And the finding that the approved geographic atrophy shots slow lesion growth comes from large multicenter trials, though those same trials did not show a measurable improvement in how well people could see3. In other words, the shots change a picture of the retina more than they change everyday sight.

The evidence for eye drops as a dry AMD treatment is, at this point, essentially absent for any product you can buy. The one eye drop in trials, GAL-101, is only in early testing and has not been shown to work5. Claims that a nutritional drop, a herbal drop, or an over-the-counter 'AMD' drop can slow the disease are not backed by the kind of trials that support supplements or shots. When the evidence is this thin, the honest label is 'unproven,' not 'natural alternative.'

A useful habit is to ask three questions of any headline. Was it tested in people, not just cells or mice? Did it slow the disease or actually help vision? And is it approved, or still in a trial? Even the approved shots slowed damage without clearly improving vision, which is why specialists treat the decision to use them as an individual one rather than an automatic yes3. Holding new drops to the same three questions will protect you from spending money and hope on products that have not earned either.

Risks, Benefits, and a Realistic Outlook

It helps to be precise about the trade. In their trials, one approved shot slowed the growth of geographic atrophy by roughly 16 to 22 percent over two years, and the other slowed it by about 14 percent after one year, which slows the spread of the damaged area but does not restore lost vision3. For some people, slowing the loss of central vision is worth a monthly or every-other-month visit. For others, the modest size of the benefit and the burden of repeated shots tip the other way. Both are reasonable conclusions, and there is no single right answer.

Repeated shots into the eye carry real, if uncommon, risks. These include serious inflammation inside the eye that has, in rare cases, caused severe and permanent vision loss, and they can raise the chance of the eye turning to wet AMD, which happened in roughly 5 to 7 of every 100 people treated monthly in the trials3. These numbers are a key reason the choice is individual. They are also a key reason a safe, effective eye drop would be so welcome if one is ever proven.

Most people with dry AMD keep useful vision for a long time, and many never reach the advanced stage. Supplements can slow progression for the right candidates, monitoring catches dangerous changes early, and low-vision tools help you keep reading and living on your own. The outlook is a population average, not a personal promise, and yours depends on your stage and your eyes. The reasonable stance is steady: use what is proven, watch for change, and follow the research rather than the marketing.

When to Call Your Eye Doctor

Dry AMD can sometimes turn into wet AMD, which is treatable but time-sensitive. If straight lines suddenly look wavy or crooked, a dark or blank spot appears near the center of your vision, or your central vision drops quickly, contact your eye doctor promptly, within a day or two, rather than waiting for your next routine visit2. A simple home tool called an Amsler grid can help you notice these changes early. Your eye doctor can show you how to use one.

If you have dry AMD, regular dilated eye exams let your team track the disease and catch a shift to the advanced or wet stage while treatment still has the most to offer. Ask how often you should be seen, whether supplements are right for your stage, and how to check your vision at home between visits. Keeping these appointments is one of the most practical things you can do, and it costs nothing but time.

An optometrist or a general ophthalmologist can follow dry AMD. The advanced-stage shots and clinical trials are handled by a retina specialist, an eye doctor with extra training in the back of the eye. Is your disease progressing, or are you curious about a trial? Ask for a referral to a retina specialist, so the person guiding your options is the one closest to the newest evidence.

Common Questions About Eye Drops and Dry AMD

No. No eye drop is approved to treat dry AMD or its advanced stage, geographic atrophy. Products marketed as 'macular support' drops have not been shown in trials to slow the disease. The treatments with real evidence behind them are oral supplements for earlier disease and shots for the advanced stage. If a drop is ever proven and approved, it will be big news. Until then, treat any drop sold for AMD as unproven, and discuss your options with your eye doctor.

The macula sits deep at the back of the eye, and a drop on the surface cannot reliably deliver enough medicine that far in. Shots, and in some cases pills, can get a useful dose to the retina. That is why nearly every treatment that has reached late-stage testing uses those routes. Researchers are trying to solve the delivery problem for drops, but it is a real scientific hurdle, not an oversight.

They are a pill, not a drop. In two large trials, the AREDS2 formula slowed how fast late dry AMD spread toward the center of vision by about 55 percent over roughly three years, for people whose atrophy started away from the center. That is a real, if modest, benefit. Supplements do not reverse damage or cure AMD. They are best matched to your specific stage, so ask your eye doctor whether they are right for you before starting.

No. The two approved geographic atrophy shots slow how fast the damaged area grows, by roughly 16 to 22 percent over two years for one and about 14 percent after one year for the other. In the trials they did not measurably improve how well people could see. They are meant to preserve remaining vision, not restore lost vision. Whether the modest benefit is worth repeated shots and their risks is a personal decision to make with a retina specialist.

Not as a treatment. GAL-101 is an experimental eye drop being tested against a placebo in an early trial. That means it has not been shown to work and is not for sale. The only way to receive it is by joining the trial, if you qualify and one is running near you. Ask your retina specialist whether that, or any other trial, is a sensible fit for your situation.

They are not a proven alternative. Herbal, nutritional, or over-the-counter 'AMD' drops have not been tested in the kind of trials that support supplements or shots, so there is no good evidence they slow the disease. 'Natural' is not the same as 'effective,' or even 'harmless.' Before trying any such product, tell your eye doctor. Relying on an unproven drop can mean missing the monitoring and proven care that actually protect your sight.

More Questions and What to Ask Your Doctor

No. Delaying proven care to wait for a drop that may be years away, or may never be proven, means going without the monitoring and treatment that help now. If you have early or intermediate dry AMD, ask about supplements and home monitoring today. If you have geographic atrophy, discuss whether a shot makes sense for you. You can follow the research and still take the steps that are available. The two are not in conflict.

Look for three things. First, that it was tested in people and not just laboratory models. Second, that it either slowed the disease or improved vision in a real trial. Third, that regulators have approved it, rather than it only appearing in a press release. Even the approved shots slow damage without clearly improving sight, so hold any new drop to at least that standard. Your retina specialist can help you separate a genuine advance from marketing.

  • What stage of dry AMD do I have, and how fast is it changing?
  • Are AREDS2-type supplements right for my stage, and which formula do you recommend?
  • If I have geographic atrophy, are the approved shots a reasonable option for me, and what are the risks in my case?
  • How should I monitor my vision at home, and what changes should prompt a same-week call?
  • Is there a clinical trial, for a drop or another treatment, that I might qualify for?
  • Should I be seen by a retina specialist, and how often should I have dilated exams?

Specialty Vision
Privacy Overview